搜索
 > 【LDL R】重组蛋白信息

LDL R信息

英文名称:LDL receptor
中文名称:低密度脂蛋白受体
靶点别称:LDLR,LDL receptor,Low-density lipoprotein receptor
上市药物数量:0
临床药物数量:8
最高研发阶段:临床三期

LDL R产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
LDR-H5281
Human
Recombinant Human LDL R Protein
LDR-H5224
Human
Human LDL R Protein, His Tag
LDR-M52H8
Mouse
Mouse LDL R Protein, His Tag
LDR-H5254
Human
Recombinant Human LDL R Protein, Fc Tag
LDR-C5222
Cynomolgus
Cynomolgus LDL R Protein, His Tag
LDR-H82E7
Human
Biotinylated Human LDL R Protein, His,Avitag
 
评论(0)
 

LDL R 分子别名

LDLR,FH,FHC,LDLCQ2

LDL R 分子背景

Low-Density Lipoprotein (LDL) Receptor is also known as LDLR, FH, FHC, LDLCQ2, and is a mosaic protein of ~840 amino acids (after removal of signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). It belongs to the Low density lipoprotein receptor gene family. LDL receptor complexes are present in clathrin-coated pits (or buds) on the cell surface, which when bound to LDL-cholesterol via adaptin, are pinched off to form clathrin-coated vesicles inside the cell. This allows LDL-cholesterol to be bound and internalized in a process known as endocytosis and prevents the LDL just diffusing around the membrane surface. This occurs in all nucleated cells (not erythrocytes), but mainly in the liver which removes ~70% of LDL from the circulation. Synthesis of receptors in the cell is regulated by the level of free intracellular cholesterol; if it is in excess for the needs of the cell then the transcription of the receptor gene will be inhibited. LDL receptors are translated by ribosomes on the endoplasmic reticulum and are modified by the Golgi apparatus before travelling in vesicles to the cell surface. LDL is directly involved in the development of atherosclerosis, due to accumulation of LDL-cholesterol in the blood. Atherosclerosis is the process responsible for the majority of cardiovascular diseases.

LDL R 参考文献

LDL R临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
CP-230821 CP-230821 临床前 辉瑞 动脉粥样硬化, 高胆固醇血症
Phosphorylcholine monoclonal antibody PC-mAb 临床二期 Dyax Pharma, Athera 心血管疾病, 动脉粥样硬化 详情
ANG-2008 (AngioChem) ANG-2008,ANG 2008,ANG2008 临床前 AngioChem 帕金森症
Axitirome CGP-26214; CGS-26214; CGP 26214; CGS 26214 临床一期 诺华 高脂血症
Serpin Peptide 16 SP16; SP-16 临床一期 Serpin Pharma 炎症, 心肌梗塞
LLG-783 (Novartis) LLG-783 临床二期 诺华 间歇性跛行, 周边动脉血管疾病 详情
CVI-LM001 C-8304; CVI-LM001 临床一期 西威埃医药技术 高脂血症
Paclitaxel trevatide ANG-1005; GRN-1005; SNG-1005 临床三期 AngioChem, 香港盛諾基醫藥科技有限公司 神经胶质瘤, 乳腺癌, 成胶质细胞瘤, 转移性脑肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定